

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, August 4, 2026

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Further to the Inside Information announcement published on June 12, 2026 (registration number 3252), in which Pharma Mar, S.A. (the “Company”) announced the preliminary top-line results from its Phase III LAGOON trial evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second line) metastatic small cell lung cancer (SCLC), the Company hereby informs that, based on the results obtained from such trial and in agreement with the U.S. Food and Drug Administration (“FDA”), its partner Jazz Pharmaceuticals intends to submit to the FDA, during the third quarter of 2026, a labeling supplement for Zepzelca® to remove the second-line metastatic SCLC indication.

This submission will not affect the first-line maintenance indication for Zepzelca®, which will remain unchanged.